Panda Biotech, a US-based industrial hemp processor, has partnered with Culturewell Trading LLP to introduce US-grown industrial hemp fibre to the Indian market. This collaboration aims to supply India’s extensive textile manufacturing sector with sustainable and traceable raw materials, addressing a growing demand for eco-friendly options in global supply chains.
Strengthening Global Textile Supply Chains
The partnership positions both companies to support the expanding global textile supply chain. India’s textile manufacturing ecosystem is a significant global player, producing a wide range of products including yarns, fabrics, denim, garments, technical textiles, and home furnishings for international brands. As the textile industry increasingly seeks traceable and sustainable raw materials, Indian mills are looking for reliable partners capable of delivering consistent quality hemp fibre at scale.
According to The Hindu BusinessLine, Culturewell Hemp has been designated as the authorized distributor and importer for Panda Biotech’s US-grown industrial hemp products across India. This arrangement is designed to strengthen supply chains for high-performance hemp fibre, particularly for textile markets focused on exports.
Meeting Demand for Sustainable Hemp Fibre
The collaboration is driven by the accelerating demand for sustainable fibres. Dixie Carter, President of Panda Biotech, noted that Indian textile mills and manufacturers are seeking scalable, high-quality, sustainable fibres that can compete globally on performance, consistency, and price. The partnership with Culturewell provides a local presence to facilitate the adoption of American-grown hemp throughout India’s textile sector.
Key aspects of this initiative include:
- Combining Panda Biotech’s mechanically processed hemp fibre with Culturewell’s market knowledge and distribution network.
- Focusing on driving the adoption of high-performance hemp materials across India’s textile sector.
- Addressing the need for fibres that meet global standards for sustainability and traceability.
This strategic move allows Indian manufacturers to access a consistent supply of industrial hemp fibre, supporting their efforts to integrate more sustainable materials into their production processes.
Certifications and Competitive Advantages
Every shipment of hemp fibre under this partnership is backed by OEKO-TEX STANDARD 100 and USDA BioPreferred certifications. These certifications underscore the commitment of both companies to sustainability, traceability, and adherence to global quality benchmarks. A Culturewell Hemp official stated that Panda Biotech’s fibre quality, consistency, traceability, and certifications position this partnership for a meaningful long-term presence in the Indian market, recognizing Indian mills as capable manufacturers.
The US-grown hemp fibre entering the Indian market holds several advantages over established European and Chinese suppliers:
- Duty Benefits: US-grown hemp fibre processed in India may qualify for duty benefits on exports to the US market, potentially offering a cost advantage over competing sources.
- Traceability: Panda Biotech’s mechanically cottonised fibre provides the traceability that Indian textile mills require to compete internationally.
- Sustainability Story: The certifications offer a verifiable sustainability narrative that resonates with export-focused brands and environmentally conscious consumers globally.
This partnership aims to provide Indian textile manufacturers with a reliable source of certified, high-quality industrial hemp fibre, enabling them to meet the evolving demands of the global market for sustainable textile products.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
